2. Search Result
Search Result
Results for "

pbmc-cell

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

3

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17427
    Emtricitabine
    5+ Cited Publications

    BW1592

    		 HIV Reverse Transcriptase Endogenous Metabolite Infection
    Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.
    Emtricitabine
  • HY-156438
    Ruvonoflast

    NT-0796

    		 NOD-like Receptor (NLR) Interleukin Related Neurological Disease
    Ruvonoflast (NT-0796) is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. Ruvonoflast inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM. Ruvonoflast is an isopropyl ester that undergoes intracellular conversion to Ruvonoflast, the carboxylic acid active species. Ruvonoflast reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. Ruvonoflast is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .
    Ruvonoflast
  • HY-17377
    Vicriviroc maleate

    SCH-417690 maleate; SCH-D maleate

    		 CCR HIV Infection Endocrinology Cancer
    Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570).
    Vicriviroc maleate
  • HY-147832
    EIF2α activator 2

    		Eukaryotic Initiation Factor (eIF) Cancer
    EIF2α activator 2 (Compound 1) is an activator of eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation. EIF2α activator 2 exhibits high potency in SRB cell proliferation assays (IC50=0.46 μM). EIF2α activator 2 exhibits antiproliferative activity againist K562 and PBMC cells with IC50s of 4.79 and 10.52 μM, respectively .
    EIF2α activator 2
  • HY-17427R
    Emtricitabine (Standard)

    BW1592 (Standard)

    		 Reference Standards HIV Reverse Transcriptase Endogenous Metabolite Infection
    Emtricitabine (Standard) is the analytical standard of Emtricitabine. This product is intended for research and analytical applications. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.
    Emtricitabine (Standard)
  • HY-153673
    PROTAC IRAK4 degrader-8

    		IRAK PROTACs Cancer
    PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC IRAK4 degrader (IC50: 15.5 nM). PROTAC IRAK4 degrader-8 degrades IRAK4 in THP-1 cells (DC50: 1.8 nM)。PROTAC IRAK4 degrader-8 also inhibits L-6 production in human whole blood and LPS-induced human PBMC cells, with IC50s of 246 nM and 2.2 nM respectively .
    PROTAC IRAK4 degrader-8
  • HY-135382
    PROTAC IRAK4 degrader-2

    		PROTACs IRAK Inflammation/Immunology Cancer
    PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC50 in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC50 of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs .
    PROTAC IRAK4 degrader-2
  • HY-179233
    PROTAC STAT6 degrader-2

    		PROTACs STAT Cancer
    PROTAC STAT6 degrader-2 is a highly efficient PROTAC degrader targeting STAT6. PROTAC STAT6 degrader-2 has a DC50 value of 1-10 nM for STAT6 in human PBMC cells and a DC50 value of less than 100 nM for STAT6 in HEK293-HIBiT-STAT6 cells. PROTAC STAT6 degrader-2 can be used for STAT6-mediated diseases .
    PROTAC STAT6 degrader-2
  • HY-17427S
    Emtricitabine-15N,d2

    BW1592-15N,d2

    		 HIV Reverse Transcriptase Endogenous Metabolite Infection
    Emtricitabine- 15N,d2 is a 15N-labeled and deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.
    Emtricitabine-15N,d2
  • HY-17427S2
    Emtricitabine-13C,15N2

    BW1592-13C,15N2

    		 Isotope-Labeled Compounds Endogenous Metabolite HIV Reverse Transcriptase Infection
    Emtricitabine- 13C, 15N2 (BW1592- 13C, 15N2) is a 13C- and 15N-labeled Emtricitabine (HY-17427). Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.
    Emtricitabine-13C,15N2
  • HY-N12988
    Dihydrobonducellin

    		Interleukin Related Inflammation/Immunology
    Dihydrobonducellin (compound 5) is a an immunomodulator. Dihydrobonducellin inhibits cell groth and the production of IL-2 and IFN-γ in PBMC cells .
    Dihydrobonducellin
  • HY-168041
    LRRK2-IN-15

    		LRRK2 BCRP Neurological Disease
    LRRK2-IN-15 is an LRRK2 inhibitor. The IC50 value for PBMC cells is 5 nM, and the IC50 value for BCRP is 1.5 μM. LRRK2-IN-15 can be used for research on Parkinson's disease .
    LRRK2-IN-15
  • HY-17427S4
    Emtricitabine-d2

    BW1592-d2

    		 Isotope-Labeled Compounds Endogenous Metabolite Reverse Transcriptase HIV Infection
    Emtricitabine-d2 (BW1592-d2) is deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.
    Emtricitabine-d2
  • HY-162579
    TLR7 agonist 22

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 22 (Compound 11a) emerges as a selective TLR7 agonist with an IC50 value of 25.86 μM. TLR7 agonist 22 inhibits the cellular HBsAg secretion and effectively activates TLR7, thereby inducing the secretion of TLR7-regulated cytokines IL-12, TNF-αand IFN-αin human PBMC cells. TLR7 agonist 22 is a promising for research in the field of developing novel immunomodulatory anti-HBV agents .
    TLR7 agonist 22

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: